More recently, our group reported four different treatment- and time-specific ct-miRNA signatures able to identify HER2 positive BC patients with differential response in terms of pCR to neoadjuvant trastuzumab, lapatinib and their combination followed by paclitaxel [15]. Here, ERBB2 is linked to breast cancer.